Kornimate/medical-research-clean huggingface dataset:
safety and efficacy of extracorporeal cytokine hemoadsorption in septic shock in critically ill cirrhotics

Conditions: Septic Shock

Summary: patients with septic shock would be screened. following this, patients meeting the inclusion and exclusion criteria will be screened and randomized to the two treatment groups. standard criteria will be considered to define refractoriness to fluids. in all patients, baseline endotoxin activity assay and blood and urine sample will be stored for looking at the effect of therapy on these factors. septic shock would be defined as clinical construct of sepsis with persisting hypotension requiring vasopressors to maintain map\>=65 mm of hg and having a serum lactate \>2 mmol/l despite adequate volume resuscitation. patients assigned to the treatment arm and who do not already have access for dialysis will have a standard hemodialysis catheter inserted in one of the femoral veins by the physician. hemoperfusion will be carried out for one session within 12 hours for all randomized patient using the adsorption columns for jianfan biotechnology co., zhuhai, china). the hemoperfusion apparatus will be connected in front of the hemodialyzer in series. the procedure would be done for 2 hours without use of heparin with use of normal saline for pipeline flushing. in patients who also require hemodialysis the dialysis would subsequently be continued. subsequent sessions of therapy would be done for patients (if required).


Eligibility criteria:
inclusion criteria: - critically ill cirrhotics with early onset septic shock (\ 4 mmol/l. exclusion criteria: * patients with age less than 18 years * severe known cardiopulmonary disease (structural or valvular heart disease, coronary artery disease, copd) * severe coagulopathy platelets \ 5 * active bleed (mucosal or variceal) * pregnancy * chronic kidney disease * extremely moribund patients with an expected life expectancy of less than 24 hours * failure to give informed consent from family members. * hemodynamic instability requiring very high dose of vasopressors, late presentation or spontaneous reversal of shock * patient enrolled in other clinical trials
a study to assess the safety and risk of hypersensitivity reactions of sulbactam-durlobactam in adults with acinetobacter baumannii-calcoaceticus (abc) complex infection

Conditions: Acinetobacter Baumannii-calcoaceticus Complex Infection (ABC)

Summary: the goal of this observational study is to evaluate the safety of sulbactam-durlobactam, as well as the risk of hypersensitivity reactions (including anaphylaxis) in participants with acinetobacter baumannii-calcoaceticus complex infection. participants will be followed for approximately 28 days in order to collect safety and reaction data.


Eligibility criteria:
inclusion criteria: * participant is ≥18 years old at the time of written informed consent and is hospitalized. * participant has provided the written informed consent. if a participant is unable to provide written informed consent due to their medical condition, the participant's legally authorized representative may consent on behalf of the participant, or the decision can be made according to the procedure permitted by local law and institutional standard operating procedures (sops). * participant has a proven or strongly suspected diagnosis of an infection caused by susceptible abc isolates, based on investigator's clinical judgment. * participant initiates treatment with sul-dur per routine clinical care. participants who receive sul-dur within 24 hours prior to enrollment are also eligible to participate. the decision to treat the participant with sul-dur is made prior to and independently of study participation. * the participant has an expected survival of \>48 hours at the time of written informed consent. exclusion criteria: * a history of significant hypersensitivity or allergic reaction to any β-lactam, or any contraindication to the use of β-lactam antibiotics

Keywords: abc infection acinetobacter baumannii-calcoaceticus complex infection hospital-acquired bacterial pneumonia ventilator-associated bacterial pneumonia sulbactam-durlobactam acinetobacter
you and me covid free

Conditions: COVID-19

Summary: observational, study that distributes rapid at-home, self-administered, sars-cov-2 antigen testing kits to households within pre-selected communities.

this observational, cohort sub-study is embedded within a larger public health intervention that distributes at-home, self-administered, sars-cov-2 antigen testing kits to households within pre-selected communities through the ccph. within this sub-study, the investigators will evaluate the socio-behavioral mechanisms of sars-cov-2 community transmission, including social interactions, health behaviors, healthcare utilization, knowledge, disease burden, and feasibility of at-home testing. the central hypothesis is that focused community intervention will reduce covid-19 transmission. the secondary hypothesis is that this intervention will increase vaccine uptake. surveys and questionnaires will be completed by participants via a qr code from the test kits that directs participants to a link. questionnaires will collect data on demographic characteristics, medical history and health status, covid testing and symptoms, social interactions, knowledge of prevention strategies, infection risk, and attitudes towards vaccines.

Eligibility criteria:
inclusion criteria: * self- reported primary residence within the pre-identified communities * age \>12 years at enrollment * provision of signed and dated informed consent form exclusion criteria: -none if above are met

Keywords: rapid test covid-19
study on thrombosis therapy in german cancer patients

Conditions: Cancer; Deep Vein Thrombosis; Pulmonary Embolism

Summary: the study aims to document the flow of german patients with cancer and acute deep vein thrombosis from first visit to diagnosis and treatment, the applied diagnostic procedures, and therapy modalities.


Eligibility criteria:
inclusion criteria: * patient with cancer and acute deep vein thrombosis and/or pulmonary embolism exclusion criteria: * life expectancy less that 6 months * age less that 18 years

Keywords: cancer thrombosis pulmonary embolism anticoagulation low molecular weight heparin
validation of laboratory techniques, strategies, and types of samples for epidemiological control in the covid-19 pandemic

Conditions: Covid19

Summary: this is a study of validation for diagnostic techniques used on epidemiological control in the covid-19 pandemic. it will be carried out in accredited public, private and university clinical laboratories of the collaborator institutions of the project based in tarija, bolivia. it is designed as a sectional validation study, using samples from specific groups of participants from the municipality of tarija grouped according to their category with respect to symptoms and viral load of covid-19. the sample is selected for convenience.


Eligibility criteria:
inclusion criteria: * symptomatic: subjects with signs and symptoms of respiratory infection less than or equal to 3 days, preferably with clinical and molecular diagnosis compatible with covid-19. * asymptomatics: subjects who have had direct contact with people infected and who have not shown any symptoms related to covid-19. * negative: individuals with negative rt-pcr testing for sars-cov-2 (reference test) who have not manifested any symptoms seven days prior to sampling. exclusion criteria: * adults under the age of 21 or over 65 * subjects with a clinical history of autoimmune disease or chemotherapy treatments. * subjects who have received transfusions or convalescent plasma in the last month prior to enrollment. * subjects with prior diagnosis of other infectious diseases such as, but not limited to aids, hepatitis b or c, tuberculosis, or any other ongoing or unresolved diseases. * subjects with malformation or oncological pathology of the upper respiratory track that may hinder sample collection, including but not limited to deviated septum, allergic rhinitis. * subjects who have not signed or can not sign the informed consent form * subjects not able to provide their complete information or access to their clinical history.

Keywords: covid 19 bolivia clinical laboratory techniques
potassium infusion for conversion of atrial fibrillation/-flutter

Conditions: Atrial Fibrillation; Atrial Flutter

Summary: atrial fibrillation is a condition in which the heart's upper chambers, the atria, contract at an abnormally rapid rate. it is a common type of arrhythmia, and occurs in 1-2% of the general population. the prevalence of atrial fibrillation increases with age. between 50 and 70% of patients with atrial fibrillation lasting \<48 hours spontaneously convert to normal sinus rhythm, and drug therapy increases the likelihood of conversion to sinus rhythm. another treatment option for conversion of atrial fibrillation and atrial flutter is electrical conversion. this is an effective treatment but requires anesthesia. current treatment strategy for medical conversion of atrial fibrillation and atrial flutter is to employ drugs that affect ion channel activity in atrial cardiomyocytes. however, such converting drugs all have potentially serious side effects and are expensive. potassium, sodium, calcium, and magnesium molecules are the most important ions causing electric current in the heart tissue. our hypothesis is that hypokalemia promotes atrial fibrillation/atrial flutter by a direct effect on cardiomyocytes. accordingly, we also hypothesize that potassium infusion may convert atrial fibrillation/atrial flutter to normal sinus rhythm. if so, this would be an inexpensive treatment with potentially very few side effects.


Eligibility criteria:
inclusion criteria: * patients with paroxysmal atrial fibrillation/atrial flutter with duration \<48 hours * plasma potassium ≤4,0 mmol/l. * age ≥ 18 år exclusion criteria: * plasma potassium \> 4,0 mmol/l * egfr \<30 ml/min * patients on antiarrhythmic therapy (flecainid, amiodarone, dronedarone or sotalol) * pregnancy * breast feeding * patients participating in a clinical trial during the last six months * addison disease, adynamia episodic hereditary, or sickle cell anemia * metabolic acidosis, ph \< 7,2

Keywords: atrial fibrillation atrial flutter potassium cardioversion
the biomarker exploratory study in prospective multicenter observational study of atezolizumab combination therapy in lung cancer (j-tail-2)

Conditions: Non-small Cell Lung Cancer; Extensive Disease Small Cell Lung Cancer

Summary: this study is implemented in association with the study "j-tail-2" ; prospective multicenter observational study of atezolizumab in patients with unresectable, locally advanced or metastatic non-small cell lung cancer, umin study id: umin000041263, to evaluate biomarkers for selection of appropriate patients in treatment with atezolizumab combination therapy.


Eligibility criteria:
inclusion criteria: inclusion/exclusion criteria of j-tail-2 study is to be applied. \ 1. patients 20 years of age or older at the time of signed consent. 2. patients with unresectable, advanced and recurrent non-small cell lung cancer. 3. patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the optimal clinical use guideline. 4. patients who signed informed consent form before enrolling the study. the consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. \ 1. patients 20 years of age or older at the time of signed consent. 2. patients with extensive disease small cell lung cancer. 3. patients who are scheduled to start atezolizumab combination therapy in clinical practice, based on the atezolizumab package insert and the optimal clinical use guideline. 4. patients who signed informed consent form before enrolling the study. the consent from a legally acceptable representative is required for the patients with uncertain capacity of judgments. however, the samples of dead cases can be used for the analysis of immune microenvironment of small cell lung cancer by disclosing information on this study. exclusion criteria: \ 1. patients who are unsuitable for enrolment into the study by the investigator's judgment. \ 1. patients who are unsuitable for enrolment into the study by the investigator's judgment.

Keywords: atezolizumab
study of the reduction of the prescriptions of benzodiazepines and related

Conditions: Depression in Old Age

Summary: the significant consumption of benzodiazepines and related drugs in the elderly outside of good practice recommendations is a major issue in the care of the elderly. adverse effects have been the subject of numerous studies, leading to falls, addictions and even deaths. the general practitioner is often faced with long-term medication intake which is not consistent with a good benefit/risk balance, but stopping or reducing the dosage remains a problem in current practice. the aftercare and geriatric rehabilitation services due to their operation (several weeks of hospitalization) seek to adapt the patient's therapies in order to obtain the most convincing benefit/risk balance possible. a reduction or withdrawal of treatments with benzodiazepines or related drugs are therefore frequently initiated.

the aim of this research is to quantify among the patients who benefited from a dosage reduction of benzodiazepines and related drugs during a stay in the geriatric care and aftercare and rehabilitation department, the number of patients who had an increase of this treatment within 12 weeks following discharge from hospitalization.

Eligibility criteria:
inclusion criteria: * major subject (≥ 75 years old) * subject discharged from a geriatric follow-up care and rehabilitation service for whom a reduction in the dosage of benzodiazepines and related drugs was carried out during hospitalization and who returned home (individual or ehpad) after hospitalization. * subject not opposing, after information, the reuse of their data for the purposes of this research. exclusion criteria: * subject having expressed opposition to participating in the study. * subject having treatment with benzodiazepine to prevent recurrence of epileptic seizures.

Keywords: depression in old age benzodiazepines drugs geriatrics
il-33, endocan and endothelial cells

Conditions: Endothelial Cell

Summary: the study aims to investigate the inflammatory response of endothelial cells to various stimulations, in particular the production of il33 and of endocan in response to allergens, agonists of microorganisms and pollutants. for that purpose, this project attempts to set up a biological collection of lung and umbilical cord endothelial cells. lung endothelial cells are resected from a surgical specimen, resulting from a lung cancer surgery. umbilical cord-derived endothelial cells are taken from the umbilical cord collected during the delivery.


Eligibility criteria:
inclusion criteria: * age \> 18 years * signed consent * pregnant woman for umbilical cord-derive-endothelial cells exclusion criteria: * age \< 18 years * refusal to participate to the study * endothelial cord-drived endothelial cells : * significant materno-foetal disorder (for example: meconium-stained amniotic fluid, chorioamnionitis, placental thrombosis, eclampsia etc.) * infection for hiv, vhb, vhc * unknown status for hiv, vhb, vhc the day of the childbirth.

Keywords: endothelial cells inflammation endothelial dysfunction il-33 endocan
nexus study for the treatment of de novo native coronary artery lesions

Conditions: Coronary Artery Disease

Summary: the objective of this study is to evaluate the effectiveness and safety of the cypher nxt sirolimus-eluting coronary stent on the bx sonic over-the-wire (otw) stent delivery system (sds) in patients with de novo native coronary artery lesions.


Eligibility criteria:
inclusion criteria: 1. male or non-pregnant female patients 18 years of age 2. diagnosis of angina pectoris as defined by canadian cardiovascular society classification (ccs i, ii, iii, iv) or unstable angina pectoris (braunwald classification b\&c, i-ii) or patients with documented silent ischemia; 3. treatment of a single de novo target lesion in a major native coronary artery; 4. target lesion is 2.5 mm and 3.5 mm in diameter (visual estimate); 5. target lesion is 30mm in length (visual estimate); 6. target lesion stenosis is \> 50% and \< 100% (visual estimate); exclusion criteria: 1. patient has experienced a q-wave or non-q-wave myocardial infarction with documented total ck \> 2 times normal within the preceding 24 hours and the ck and ck-mb enzymes remain above normal at the time of treatment; 2. has unstable angina classified as braunwald iii b or c, or is having a peri-infarction angina; 3. significant (\> 50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff; 4. documented left ventricular ejection fraction 25%; 5. totally occluded vessel (timi 0 level); 6. impaired renal function (creatinine \> 3.0 mg/dl) at the time of treatment;
cephalic version by acupuncture for breech presentation

Conditions: Breech Presentation

Summary: we want to study the efficiency of acupuncture for cephalic version of breech presentation during pregnancy. several randomized studies show that acupuncture may be useful in version of breech presentation, but none with a sham. protocol : * inclusion of patients with fetus in breech presentation at 32-34 weeks of pregnancy. * randomization. first group : acupuncture by stimulation of "67 bladder" point.second group : stimulation of "45 stomach" point (sham). * ultrasonographic control of presentation at 35 weeks.


Eligibility criteria:
inclusion criteria: * single pregnancy at 32-34 weeks of pregnancy. * fetus in breech presentation. exclusion criteria: * twins. * story of preterm birth or any preterm birth risk * fetal malformations, abnormal karyotype

Keywords: acupuncture, moxybustion, cephalic version, breech presentation
autogenous demineralized dentin block graft versus particulate deproteinized bovine bone graft for alveolar ridge preservation

Conditions: Alveolar Bone Loss

Summary: the aim of this trial is to compare the effect of autogenous demineralized dentin block graft (addbg) versus particulate deproteinized bovine bone graft (pdbbg) on alveolar ridge preservation after extraction of non-restorable single rooted teeth

many studies have reported an approximately 50% reduction in alveolar bone both the horizontal and vertical directions over 12 months with more than two-thirds of the reduction occurring in the first three months after extraction. alveolar ridge preservation is a procedure that attempts to reduce bone dimensional changes that naturally take place following tooth extraction. during the last decade, efforts have been made to confirm procedures that can prevent bone resorption after extraction. the use of bone grafts aim to promote bone healing and assist bone regeneration. various types of materials are used for socket preservation, such as autogenous bone, allograft bone, xenograft materials, and alloplast materials. the deproteinized bovine bone has been tested in vitro and in vivo in the alveolar ridge preservation and plays a positive role in osteoconductive function. guided bone regeneration (gbr) procedure has been developed to counteract alveolar ridge bone resorption. gbr technology with xenografts, such as the deproteinized bovine bone mineral, could lead to bone regeneration. moreover, root dentin block is composed of type i collagen matrix with several osteoinductive non-collagenous proteins such as bone morphogenetic proteins (bmp) and dentin matrix proteins. geometrically, alveolar bone morphology was maintained by dentin block graft as well as it has micropores (dentinal tubules) of 3-5 μm diameter and macropores of 0.2-0.3 mm diameter for enhancing osteoinductive and osteoconductive functions. both demineralized dentin block and particulate deproteinized bovine bone grafts with or without collagen membrane have been utilized for alveolar ridge preservation or augmentation but the superiority of one form over the other is not yet clear

Eligibility criteria:
inclusion criteria: * non-restorable tooth indicated for extraction * single-rooted teeth * motivated patients, agree to sign informed consent and complete the follow-up period exclusion criteria: * pregnant females * active infection at extraction site * smokers * systemic conditions affecting healing (e.g. diabetes, medications as bisphosphonates...)
efficacy and safety of imab362 in combination with the eox regimen for cldn18.2-positive gastric cancer

Conditions: CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction; CLDN18.2-positive Adenocarcinoma of Esophagus; CLDN18.2-positive Gastric Adenocarcinoma

Summary: the purpose of the trial is to assess the therapeutic effects and the safety profile of imab362 combined with eox (epirubicin, oxaliplatin, capecitabine) as first-line treatment for patients with advanced adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction compared to eox alone. furthermore, sufficient binding of imab362 to the target cells is necessary for antitumoral activity. thus, two dose levels ensuring a serum level above the in vitro predicted clinical efficacy threshold will be investigated.


Eligibility criteria:
inclusion criteria: * histologically confirmed adenocarcinoma of the stomach, the esophagus or the gastroesophageal junction * inoperable locally advanced disease or resections with r2 outcome or recurrent or metastatic disease. * cldn18.2 expression confirmed by immunohistochemistry in paraffin embedded tumor tissue sample. * measurable and/or non-measurable disease as defined according to recistv1.1 * age ≥ 18 years * written informed consent form * ecog performance status (ps) 0-1 * life expectancy \> 3 months * her2/neu negative patients and patients with her2/neu positive status but not eligible to trastuzumab therapy in discretion of the investigator. * adequate cardiac, hepatic, renal, hematologic function. exclusion criteria: * prior severe allergic reaction or intolerance to a monoclonal antibody, to the chemotherapeutics used in this study or any excipient in the respective formulations. * previous chemotherapy for advanced disease. * previous perioperative chemotherapy with curative intention within 6 months of start of study treatment. if interval is longer than 6 months (counted from the stop date of the perioperative chemotherapy), patients are allowed. * known hiv infection or known symptomatic hepatitis (a, b, c). * symptomatic cerebral metastases. * pregnancy or breastfeeding. * previous treatments with maximum cumulative doses of epirubicin \> 500 mg/m² and/or other anthracyclines and anthracenediones. * known dihydropyrimidine dehydrogenase (dpd) deficiency.

Keywords: imab362 asp8951 zolbetuximab